Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Dominant Dystrophic Epidermolysis Bullosa: later-stage trial registry
2 of 2 indexed Dominant Dystrophic Epidermolysis Bullosa trials are currently recruiting, with more weight in Phase 3-4.
Corpus placement: #7,188 of 28,707 conditions by registered trial count.
2 US clinical trials · 2 currently recruiting · #7,188 of 28,707 conditions by registered trial count
Dominant Dystrophic Epidermolysis Bullosa: 2 US clinical trials tracked, 2 recruiting.
Dominant Dystrophic Epidermolysis Bullosa is the subject of 2 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most active sponsor is Krystal Biotech, running 2 of these trials.
Enrollment posture brief
Registry condition dominant-dystrophic-epidermolysis-bullosa
OPEN 2 | RECR 100% | LATE 1 | EARLY 0 | RANK #7188 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)
Dominant Dystrophic Epidermolysis Bullosa lists 2 open slots (100% of 2 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Dominant Dystrophic Epidermolysis Bullosa on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Dominant Dystrophic Epidermolysis Bullosa is recruiting above its size-band peers.
2 of 2 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
2 total, page 1 of 1
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Dominant Dystrophic Epidermolysis Bullosa records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Dominant Dystrophic Epidermolysis Bullosa trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Dominant Dystrophic Epidermolysis Bullosa page
2 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 2 Dominant Dystrophic Epidermolysis Bullosa trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Krystal Biotech sponsors the most Dominant Dystrophic Epidermolysis Bullosa trials on record, review their full trial history before evaluating a specific study. See Krystal Biotech's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Dominant Dystrophic Epidermolysis Bullosa condition card totals 2 registered trials; most-linked intervention Placebo; top US site state Florida. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.